47 results on '"Maisey, Nick"'
Search Results
2. Association of dynamic contrast-enhanced MRI and 18F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancer
3. Cultivating human connection in the everyday: a practical model for solidarity
4. Association of dynamic contrast-enhanced MRI and 18F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancer
5. Incidence and relevance of clinically indeterminate nonregional lymph nodes in the treatment of oesophageal cancer
6. ASO Visual Abstract: Clinical Relevance of the Tumor Location-Modified Laurén Classification System of Gastric Cancer in a Western Population
7. Prehabilitation exercise before oesophagectomy: long-term follow-up of patients declining/withdrawing from the program
8. Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom.
9. Feasibility Of Exercise Prehabilitation During Neo-adjuvant Chemotherapy In Oesophago-gastric Cancer Surgery: 1549 Board #311 May 30 10:30 AM - 12:00 PM
10. OGC P20 Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients undergoing surgical resection for locally advanced oesophageal adenocarcinoma
11. OGC O02 The prognostic effect of pathological lymph node regression after neoadjuvant chemotherapy for oesophageal adenocarcinoma – a multicentre study
12. 568. THE PROGNOSTIC EFFECT OF PATHOLOGICAL LYMPH NODE REGRESSION AFTER NEOADJUVANT CHEMOTHERAPY FOR OESOPHAGEAL ADENOCARCINOMA – A MULTICENTRE STUDY
13. 354. THE PARADIGM OF INACCURACIES IN STAGING EARLY OESOPHAGEAL ADENOCARCINOMA
14. 577. FDG PT-CT METABOLIC TUMOUR AND NODAL RESPONSE AS A PREDICTOR OF PATHOLOGICAL RESPONSE AND SURVIVAL IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA
15. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial
16. Effect of peri-operative chemotherapy regimen on survival in the treatment of locally advanced oesophago-gastric adenocarcinoma – A comparison of the FLOT and ‘MAGIC’ regimens
17. Exercise prehabilitation during neoadjuvant chemotherapy may enhance tumour regression in oesophageal cancer: results from a prospective non-randomised trial
18. P-OGC22 Incidence and relevance of clinically indeterminate non-regional lymph nodes in the treatment of oesophageal cancer
19. Predicting response to neoadjuvant chemotherapy in patients with oesophageal adenocarcinoma
20. Assessment of sarcopenia and changes in body composition after neoadjuvant chemotherapy and associations with clinical outcomes in oesophageal cancer
21. Colorectal liver metastases
22. Efficacy of Reduced-Intensity Chemotherapy With Oxaliplatin and Capecitabine on Quality of Life and Cancer Control Among Older and Frail Patients With Advanced Gastroesophageal Cancer
23. 646 PREDICTING RESPONSE TO NEOADJUVANT CHEMOTHERAPY IN PATIENTS WITH OESOPHAGEAL ADENOCARCINOMA
24. Nivolumab in gastric/gastroesophageal junction cancer: real-world data from UK Early Access to Medicines Scheme
25. Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins
26. Impact of primary tumour location in patients with RAS/RAF wild- type metastatic colorectal cancer treated with first-line chemotherapy & anti-EGFR antibodies: A retrospective study at Guy's Cancer Centre
27. P107 PREDICTION OF A POSITIVE CIRCUMFERENTIAL RESECTION MARGIN IN ADENOCARCINOMA OF THE ESOPHAGUS
28. Optimising Chemotherapy for Frail and Older Patients With Advanced Gastroesophageal Cancer: The GO2 Phase III Trial
29. The role of surgery after prolonged primary chemotherapy for advanced oesophageal adenocarcinoma.
30. Lymphoma
31. Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer
32. Current therapy and future prospects in lymphoma
33. PS02.166: OESOPHAGO-GASTRIC CANCER PATIENTS OPERATED ON IN THE PRIVATE SECTOR SURVIVE LONGER THAN NHS PATIENTS
34. Reply to R.C. Turkington et al
35. Tumor Stage After Neoadjuvant Chemotherapy Determines Survival After Surgery for Adenocarcinoma of the Esophagus and Esophagogastric Junction
36. A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: Results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO)
37. P-0143 The Role of Chemotherapy in Advanced Biliary Tract Cancers: Clinical Experience from a Specialist UK Cancer Centre
38. Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
39. Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
40. Pilot Evaluation of the Value of FDG PET-CT after One and Two Cycles of Salvage Chemotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s and Hodgkin’s Lymphoma
41. Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
42. Antitumor Necrosis Factor (TNF-a) Antibodies in the Treatment of Renal Cell Cancer
43. Treatment of SW620 Cells with Tomudex and Oxaliplatin Induces Changes in 2-Deoxy-D-Glucose Incorporation Associated with Modifications in Glucose Transport.
44. Clinical Tumor Staging of Adenocarcinoma of the Esophagus and Esophagogastric Junction.
45. Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins
46. Association of dynamic contrast-enhanced MRI and 18 F-Fluorodeoxyglucose PET/CT parameters with neoadjuvant therapy response and survival in esophagogastric cancer.
47. Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.